Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2019Journal of Immunology ResearchOpen Access

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

FBFan BaiShanxi Medical UniversityGLGang Gang LiSecond Affiliated Hospital of Xi'an Jiaotong UniversityQLQingmin LiuUniversity of Missouri

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bai et al. (2019) studied this question.

synapsesocial.com/papers/69dd535d5ea84e55561016f0https://doi.org/10.1155/2019/2546161
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis2016 · 849 citations
  2. 2Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis2017 · 141 citations